Minoxidil (Topical & Oral)
Everyday exposureBeauty & personal careAlso called · 9 names▾▴
minoxidil hair loss, topical minoxidil, oral minoxidil, low-dose oral minoxidil, minoxidil pregnancy, minoxidil breastfeeding, hair growth medication, hair regrowth medicine, hair loss treatment
Hair
General information · effects depend on amount, timing, and how it is used. About these sources
Research strength: 2 / 5
UK product information says topical minoxidil must not be used during pregnancy, and the FDA topical label warns it may be harmful. The FDA tablet label reports fetal resorption in rabbits, but not rats, at five times the maximum recommended oral hypertension dose and says controlled human pregnancy studies are absent. Smorlesi et al. described one 2003 pregnancy with fetal malformations after topical use, while Shapiro's 2003 study reported no apparent increase in adverse pregnancy outcomes but gave no pregnancy count or outcome details; neither finding establishes a cause or rules out harm. The FDA boxed warning reserves oral tablets for patients whose hypertension does not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents, and warns of pericardial effusion, sometimes tamponade, and worsening angina. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray
- FDA-approved Rogaine topical minoxidil labeling, 2026Drug company label
- DailyMed: Minoxidil tablet labelDrug company label
- Smorlesi et al. 2003: Topically applied minoxidil may cause fetal malformationUS government
- Shapiro 2003: Safety of topical minoxidil solutionUS government
Research strength: 2 / 5
The reviewed sources do not provide trimester-specific risk estimates. UK product information says topical minoxidil must not be used during pregnancy, and the FDA topical label warns it may be harmful. The FDA tablet label reports fetal resorption in rabbits, but not rats, at five times the maximum recommended oral hypertension dose and says controlled human pregnancy studies are absent. Smorlesi et al. described one 2003 pregnancy with fetal malformations after topical use, while Shapiro's 2003 study reported no apparent increase in adverse pregnancy outcomes but gave no pregnancy count or outcome details. The FDA boxed warning reserves oral tablets for patients whose hypertension does not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents, and warns of pericardial effusion, sometimes tamponade, and worsening angina. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray
- FDA-approved Rogaine topical minoxidil labeling, 2026Drug company label
- DailyMed: Minoxidil tablet labelDrug company label
- Smorlesi et al. 2003: Topically applied minoxidil may cause fetal malformationUS government
- Shapiro 2003: Safety of topical minoxidil solutionUS government
- Gupta et al. 2026: Delphi consensus for minoxidil in hair-transplant patientsUS government
Research strength: 2 / 5
The reviewed sources do not provide trimester-specific risk estimates. UK product information says topical minoxidil must not be used during pregnancy, and the FDA topical label warns it may be harmful. The FDA tablet label reports fetal resorption in rabbits, but not rats, at five times the maximum recommended oral hypertension dose and says controlled human pregnancy studies are absent. Smorlesi et al. described one 2003 pregnancy with fetal malformations after topical use, while Shapiro's 2003 study reported no apparent increase in adverse pregnancy outcomes but gave no pregnancy count or outcome details. The FDA boxed warning reserves oral tablets for patients whose hypertension does not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents, and warns of pericardial effusion, sometimes tamponade, and worsening angina. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray
- FDA-approved Rogaine topical minoxidil labeling, 2026Drug company label
- DailyMed: Minoxidil tablet labelDrug company label
- Smorlesi et al. 2003: Topically applied minoxidil may cause fetal malformationUS government
- Shapiro 2003: Safety of topical minoxidil solutionUS government
- Gupta et al. 2026: Delphi consensus for minoxidil in hair-transplant patientsUS government
Minoxidil (Topical & Oral) — Breastfeeding
Research strength: 2 / 5
LactMed says topical use may be acceptable once breastfeeding is established if infant contact with treated skin is prevented, and urges caution with oral doses, especially larger doses or a newborn. UK product information says minoxidil must not be used by breastfeeding mothers, and the FDA topical label warns it may be harmful during breastfeeding. EMA concluded a causal link between topical minoxidil and infant hypertrichosis after accidental skin contact was at least a reasonable possibility; the FDA's 2026 label added a child-contact warning after reports of reversible excess hair growth. Suresh et al. (2025) counted 45 infants aged 0-23 months among 2,664 minoxidil-suspected hypertrichosis reports, but spontaneous reports do not establish a rate or prove that maternal use caused each event. The FDA tablet boxed warning reserves oral tablets for patients whose hypertension does not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents, and warns of pericardial effusion, sometimes tamponade, and worsening angina. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- LactMed: MinoxidilUS government
- UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray
- FDA-approved Rogaine topical minoxidil labeling, 2026Drug company label
- EMA: Minoxidil topical formulation, PSUSA-00002067-202310EU agencyEuropean guidance
- Suresh et al. 2025: Topical minoxidil and infantile hypertrichosis reports
- Gupta et al. 2026: Delphi consensus for minoxidil in hair-transplant patientsUS government
Pregnancy
The FDA tablet label reports increased fetal resorption in rabbits, but not rats, at five times the maximum recommended oral antihypertensive dose. It reports no birth-defect effects in rats or rabbits at the studied doses. A subcutaneous dose of 80 mg/kg/day harmed the mother but did not cause birth defects; higher injected doses affected development in rats. The label says adequate, well-controlled human pregnancy studies are absent. These animal findings followed oral or injected exposure and do not directly measure scalp application or low-dose oral hair-loss use. Human evidence is limited. Smorlesi et al. (2003) described a pregnancy with fetal brain, heart, and vascular malformations after daily 2% topical minoxidil; the report cannot establish a cause. Rojansky et al. (2002) described a fetus with severe caudal and renal malformations after maternal minoxidil solution use, but the mother also used trimethoprim-sulfamethoxazole during the first trimester. Shapiro's 2003 prospective observational study reported no apparent increase in adverse pregnancy outcomes, but its abstract gives no pregnancy count or outcome details. The FDA label says controlled human data are absent, and the 2026 review by Brinks et al. describes the evidence as conflicting. UK product information says minoxidil must not be used during pregnancy and cites possible fetal harm based on animal studies. The FDA topical label says it may be harmful if used during pregnancy. A 2026 modified Delphi consensus for pattern-hair-loss treatment also says minoxidil should not be used during pregnancy, but it reports expert agreement, not pregnancy outcomes. Available sources do not give trimester-specific risks or quantify the chance of a fetal outcome.
Breastfeeding
LactMed says topical minoxidil is acceptable once breastfeeding is established when infant contact with treated skin is prevented. It recommends caution with oral minoxidil, particularly with higher maternal doses or a nursing newborn. LactMed describes one maternal oral milk-level report and says published infant blood levels were not found; no topical milk-level report is identified in its entry. LactMed also describes a preterm breastfed infant with reversible facial hypertrichosis while the mother used topical 5% minoxidil, but the report did not establish whether exposure was through milk or skin contact. EMA's 2024 safety review concluded that a causal relationship between topical minoxidil and infant hypertrichosis after inadvertent topical exposure was at least a reasonable possibility, and it called for product-information and packaging changes. Suresh et al. (2025) analyzed VigiBase reports through March 2025: 45 of 2,664 minoxidil-suspected infantile-hypertrichosis reports involved children aged 0-23 months; the reported exposure was maternal in 22.2%, accidental in 44.4%, and unknown in 33.3%. These reports cannot estimate the rate of an event or establish how each child was exposed. UK product information says minoxidil must not be used by breastfeeding mothers, and the FDA topical label warns it may be harmful during breastfeeding. A 2026 modified Delphi consensus also advises against minoxidil during breastfeeding, but provides no infant-outcome data.
Minoxidil is the active drug. Topical products are scalp solutions or foams, with 2% or 5% minoxidil in U.S. product labels. The 2% topical label lists alcohol, propylene glycol, and purified water as inactive ingredients. Oral tablets contain 2.5 mg or 10 mg minoxidil and list lactose, silicon dioxide, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate as inactive ingredients. UK product information reports that about 1-2% of topical minoxidil is systemically absorbed, compared with 90-100% for oral formulations. Oral tablets are labeled for certain cases of difficult-to-control hypertension; promoting hair growth with tablets is not an approved indication.
What was tested
The FDA tablet label summarizes rat and rabbit reproductive studies using oral or subcutaneous doses. It does not provide controlled human pregnancy results. Smorlesi et al. (2003) and Rojansky et al. (2002) are case reports; the latter includes a concurrent first-trimester medicine exposure. Shapiro (2003) followed topical-minoxidil users prospectively for one year, but the PubMed abstract does not report the number of pregnancies or specific pregnancy outcomes. LactMed reports one maternal oral milk-level case and an infant case during maternal topical use; its cited 1985 and 2022 primary records did not provide abstracts in PubMed. The 2025 Suresh study is a retrospective analysis of spontaneous pharmacovigilance reports, not a study that can estimate incidence. The 2026 Gupta consensus used a modified Delphi process with hair-transplant specialists and did not test pregnancy or breastfeeding outcomes.
Minoxidil during pregnancy
- Source A says
- UK product information says minoxidil must not be used during pregnancy, the FDA topical label warns it may be harmful, and a 2026 modified Delphi consensus advises against use. (UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray, FDA-approved Rogaine topical minoxidil labeling, 2026, Gupta et al. 2026: Low-dose oral minoxidil and topical minoxidil consensus recommendations)
- Source B says
- Shapiro's 2003 prospective observational study reported no apparent increased risk for adverse pregnancy outcomes with topical minoxidil, but its abstract gives no pregnancy count or outcome details. (Shapiro 2003: Safety of topical minoxidil solution: a one-year, prospective, observational study)
- Why they differ
- Product information and the Delphi panel take a precautionary position in a setting with animal findings and limited human data. Shapiro's abstract reports no apparent increase, but the missing pregnancy count and outcome details limit what can be concluded from that statement.
- What the evidence shows overall
- The rating remains Generally Avoided under current product information, but the available evidence does not quantify the risk or establish that topical minoxidil caused the reported anomaly cases. Animal oral or injected findings should not be treated as direct evidence about scalp application or low-dose oral hair-loss use.
Topical minoxidil during breastfeeding
- Source A says
- LactMed describes topical use as acceptable once breastfeeding is established when infant contact with treated skin is prevented; it urges caution with oral use, especially at higher doses or with a newborn. (LactMed: Minoxidil)
- Source B says
- UK product information says minoxidil must not be used by breastfeeding mothers, the FDA topical label warns it may be harmful during breastfeeding, and EMA identifies a reasonable possibility of infant hypertrichosis after accidental topical contact. (UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray, FDA-approved Rogaine topical minoxidil labeling, 2026, EMA: Minoxidil topical formulation, PSUSA-00002067-202310)
- Why they differ
- LactMed gives route-specific guidance and focuses on contact with treated skin, while product information uses a broader restriction. The EMA signal concerns accidental skin contact and does not show that minoxidil passed through milk in those cases.
- What the evidence shows overall
- The rating remains Use With Monitoring because LactMed's route-specific assessment differs from product labeling and regulators recognize an infant contact signal. Oral milk transfer is documented in one maternal case, but infant levels were not found and the topical infant report did not establish the exposure route.
- LactMed describes maternal topical minoxidil as acceptable once breastfeeding is established when infant contact with treated skin is prevented; it urges caution with oral use, particularly with higher maternal doses or a nursing newborn. (LactMed: Minoxidil)
- The FDA-approved Rogaine label says to prevent children from touching minoxidil application sites and reports reversible infant excess hair growth after skin contact with a caregiver's treated sites. (FDA-approved Rogaine topical minoxidil labeling, 2026)
- The FDA tablet label reserves oral minoxidil for certain cases of hypertension not controlled by maximum therapeutic doses of a diuretic plus two other antihypertensive medicines and warns of pericardial effusion and worsening angina. (DailyMed: Minoxidil tablet label)
General research, not specific to pregnancy.
Topical minoxidil products are labeled for scalp hair regrowth, while oral minoxidil tablets are labeled for certain cases of severe hypertension, not hair growth.
- The FDA tablet label says use of minoxidil tablets to promote hair growth is not an approved indication and lists resistant hypertension as the approved use. Its boxed warning describes pericardial effusion, sometimes progressing to tamponade, and worsening angina. (DailyMed: Minoxidil tablet label, Bryant Ranch Prepack)
- The FDA-approved 2% topical label is for scalp hair regrowth and says it is not for hair loss associated with childbirth. It lists alcohol, propylene glycol, and purified water as inactive ingredients. (FDA-approved Rogaine topical minoxidil labeling, 2026)
- UK product information reports about 1-2% systemic absorption after topical application, compared with 90-100% for oral formulations; these values describe absorption and do not establish pregnancy or infant outcomes. (UK Summary of Product Characteristics: Minoxidil 5% cutaneous spray)
Experiences from moms and non-medical voices. Not medical evidence.
- LactMed: MinoxidilUS governmentSecondaryPage dated 2026-05-15
- FDA-approved Rogaine topical minoxidil labeling, 2026Drug company labelTertiaryPage dated 2026-01-14
- FDA: Rogaine supplemental labeling approval letter, 2026Drug company labelSecondaryPage dated 2026-01-14Independent check
- DailyMed: Minoxidil tablet label, Bryant Ranch PrepackDrug company labelTertiaryPage dated 2026-07-14
- UK Summary of Product Characteristics: Minoxidil 5% cutaneous sprayTertiaryPage dated 2025-01-14Independent check
- EMA: Minoxidil topical formulation, PSUSA-00002067-202310EU agencySecondaryIndependent checkEuropean guidance
- Suresh et al. 2025: Understanding the safety profile of topical minoxidilPrimaryPage dated 2025-12-20Independent check
- Shapiro 2003: Safety of topical minoxidil solution: a one-year, prospective, observational studyUS governmentPrimaryIndependent check
- Smorlesi et al. 2003: Topically applied minoxidil may cause fetal malformationUS governmentPrimaryIndependent check
- Rojansky et al. 2002: Extreme caudal agenesis. Possible drug-related etiology?US governmentPrimaryIndependent check
- Brinks et al. 2026: Safety and clinical considerations of alopecia therapies during pregnancyUS governmentPrimaryPage dated 2026-06-25Independent check
- Gupta et al. 2026: Low-dose oral minoxidil and topical minoxidil consensus recommendationsUS governmentPrimaryIndependent check
Last reviewed 2026-10-18
Independent check 2026-10-18
Not yet clinician-reviewed
Ask your provider about your situation.